MapLight Therapeutics Inc.
Price
Key statistics
- Forward rate
- $0.00
- Yield
- 0.00%
- Payout ratio
- 0.00%
- Frequency
- Unknown
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. The company’s current pipeline centers on brain and neuroscience programs aimed at conditions such as schizophrenia, Alzheimer’s disease psychosis, autism spectrum disorder, Parkinson’s disease motor symptoms, and other neuropsychiatric disorders. Its lead candidate, ML-007C-MA, is being developed as an oral fixed-dose combination therapy, while additional product candidates include ML-004, ML-021, ML-055, and ML-009. MapLight Therapeutics also uses a discovery platform designed to identify neural circuits linked to disease and guide therapeutic modulation. The company is based in Redwood City, California, and focuses on translating circuit-based neuroscience into targeted medicines for patients with serious brain disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Christopher A. Kroeger M.B.A., M.D., Ph.D.
- Employees
- 133
- Headquarters
- Redwood City, CA, United States
- Website
- www.maplightrx.com